James Hardie disappoints on earnings front, flags lower full-year profit

Published 03-FEB-2017 12:35 P.M.


1 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Global building materials group, James Hardie (ASX: JHX) today announced its third quarter results for fiscal 2017.

In the three months to December 31, 2016 adjusted earnings before interest and tax was $73.5 million, a decrease of 10% compared with the previous corresponding quarter.

This decline occurred despite the group achieving 10% year-on-year sales growth for the quarter.

James Hardie Chief Executive Louis Gries said, “The volume performance was offset by manufacturing inefficiencies and start-up costs associated with increasing our network capacity”.

Leading up to the release of the third quarter result, analysts at Citi commented that the key focus will be on full-year guidance which it anticipated would be a reiteration of underlying net profit in a range between US$250 million and US$270 million.

The broker was forecasting a full-year net profit of $265 million prior to the release of the third quarter figures.

However, James Hardie has disappointed with its guidance, lowering its expectations to a range between US$245 million and US$255 million.

The company was also guarded with its commentary on housing activity, saying “Management cautions that although US housing activity has been improving, market conditions remain somewhat uncertain and some input costs remain volatile”.

Given that Thursday’s closing share price of $20.85 represents a slight premium to the consensus 12-month price target of $20.57 (Citi: $20.30), there could be some selling at current levels.

It should be noted that broker projections and price targets are only estimates and may not be met. Also, historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free